Загрузка...
Continuous inhibition of epidermal growth factor receptor phosphorylation by erlotinib enhances antitumor activity of chemotherapy in erlotinib-resistant tumor xenografts
Erlotinib, an epidermal growth factor receptor tyrosine kinase inhibitor, has been shown to have benefits for non-small cell lung cancer and pancreatic cancer patients; however, almost all patients develop progressive disease during the therapy. On the other hand, it has been reported that a tumor c...
Сохранить в:
| Главные авторы: | , , , , |
|---|---|
| Формат: | Artigo |
| Язык: | Inglês |
| Опубликовано: |
D.A. Spandidos
2011
|
| Предметы: | |
| Online-ссылка: | https://ncbi.nlm.nih.gov/pmc/articles/PMC3583539/ https://ncbi.nlm.nih.gov/pubmed/22209766 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3892/or.2011.1614 |
| Метки: |
Добавить метку
Нет меток, Требуется 1-ая метка записи!
|